FENC

Fennec Pharmaceuticals Inc

11.62

Nov 13 • 3:59 PM ET +0.72 (6.61%)

11.62

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Nov 13, 2:33 AMFennec reports fiscal Q3 2026 results, beats estimates with revenue $19.6M (+57% YoY), non-GAAP EPS $0.12 and record PEDMARK sales up 56%

Peers: HRTX CHRS RIGL VSTM CRMD ZVRA ETON ADCT ANIP CTOR

| Held by: VTI IWM IWO VTWO IWC VTWG RSSL VTHR FLQS ITWO

Scroll to Statements

Index	RUT
Market Cap	410.25M
Enterprise Value	361.57M
Income	1.67M
Sales	66.37M
Book/sh	1.40
Cash/sh	1.38
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	35
IPO	Oct 22, 2003

P/E	695.81
Forward P/E	12.31
PEG	-
P/S	6.18
P/B	8.32
P/C	8.43
P/FCF	347.67
EV/EBITDA	108.58
EV/Sales	5.45
Quick Ratio	5.95
Current Ratio	6.11
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	0.02
EPS next Y	0.94
EPS next Q	0.15
EPS this Y	193.71%
EPS next Y	187.80%
EPS next 5Y	-
EPS past 3/5Y	27.71% 14.90%
Sales past 3/5Y	207.52% 204.69%
EPS Y/Y TTM	112.65%
Sales Y/Y TTM	71.09%
EPS Q/Q	632.31%
Sales Q/Q	57.34%
Earnings	Nov 12 BMO
EPS/Sales Surpr.	25.00% 3.92%

Insider Own	14.17%
Insider Trans	-2.78%
Inst Own	56.97%
Inst Trans	1.66%
ROA	2.51%
ROE	7.47%
ROIC	3.39%
Gross Margin	94.13%
Oper. Margin	4.91%
Profit Margin	2.52%
SMA20	10.82%
SMA50	9.16%
SMA200	24.25%
Trades

Shs Outstand	35.22M
Shs Float	30.10M
Short Float	1.51%
Short Ratio	2.51
Short Interest	0.45M
52W High	13.25 -12.30%
52W Low	5.65 105.66%
Volatility	9.16% 7.01%
ATR (14)	0.74
RSI (14)	61.12
Beta	1.21
Rel Volume	2.55
Avg Volume	180.99K
Volume	461,340

Perf Week	18.45%
Perf Month	12.27%
Perf Quarter	-1.78%
Perf Half Y	19.18%
Perf YTD	50.91%
Perf Year	51.11%
Perf 3Y	47.65%
Perf 5Y	21.93%
Perf 10Y	545.56%
Recom	1.00
Target Price	17.20
Prev Close	10.90
Price	11.62
Change %	6.61%

Consensus

Strong Buy

Avg. Price Target

$17.20

Implied Upside

+48.0%

Analysts6incl. previous ratings

Rating Distribution6 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Feb 12, 2026	Initiated	RB. Riley Securities	Buy	$16	+37.7%
Jan 09, 2026	Initiated	PPiper Sandler	Overweight
Nov 22, 2022	Upgrade	CCantor Fitzgerald	Neutral → Overweight	$9 → $12	+3.3%
Sep 07, 2022	Initiated	CCapitalOne	Overweight	$11	-5.3%
Aug 08, 2022	Resumed	CCraig Hallum	Buy	$14	+20.5%
Jun 05, 2020	Initiated	CCantor Fitzgerald	Overweight	$18	+54.9%
Oct 11, 2018	Initiated	GGoldman	Buy

Nov-12-26 10:49AM	Fennec Pharmaceuticals Converts PEDMARK Momentum Into A 30% EBITDA Margin, Even As Year-Over-Year Growth Cools And Guidance Stays Absent (Earnings Whispers)
06:03AM	Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-26 02:31PM	Fennec's Record July Meets A Sliding Stock As Project Ignite Faces Its Proof Quarter (Earnings Whispers)
05:50AM	Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026 (GlobeNewswire)
Sep-17-26 07:30AM	Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark in Japan at SIOP 2026 (GlobeNewswire)
05:02PM	Loading…
Aug-11-26 05:02PM	Fennec Pharmaceuticals Inc (FENC) (Q2 2026) Earnings Call Highlights: Record Sales and ... (GuruFocus.com) +16.82% -7.43%
10:20AM	Fennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates (InvestorsHub)
07:01AM	Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-26 07:01AM	Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026 (GlobeNewswire)
Jun-22-26 06:00AM	Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +5.19%
Jun-15-26 06:00AM	Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jun-10-26 04:30PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
May-21-26 06:01PM	Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK at the 2026 ASCO Annual Meeting (GlobeNewswire)
May-18-26 04:30PM	Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-14-26 07:03PM	Fennec Pharmaceuticals Inc (FENC) Q1 2026 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com) +36.48% +5.52%
08:47AM	Loading…
08:47AM	Fennec Pharmaceuticals Shares Rise After Earnings and Revenue Beat Forecasts (FENC) (InvestorsHub)
06:30AM	Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-07-26 06:36AM	Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026 (GlobeNewswire)
Apr-21-26 04:30PM	Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting (GlobeNewswire)
Apr-07-26 07:03AM	Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center (GlobeNewswire)
Mar-31-26 06:00AM	Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.59%
Mar-24-26 03:02PM	Fennec Pharmaceuticals Inc (FENC) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com) -19.19%
01:20PM	Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses (Newsfile)
07:00AM	Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-18-26 07:08AM	Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026 (GlobeNewswire)
Mar-16-26 08:08AM	Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation (GlobeNewswire)
Mar-05-26 10:00AM	Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline (Zacks)
Mar-04-26 07:05AM	Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute (GlobeNewswire)
Mar-02-26 10:00AM	Adherex Technologies Inc. (FENC) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
07:15AM	Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:15AM	Loading…
Feb-26-26 08:15AM	Certara, Inc. (CERT) Q4 Earnings Lag Estimates (Zacks)
Feb-24-26 11:00AM	Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
Feb-20-26 07:03AM	Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK in Treating Adults with Head & Neck Cancers (GlobeNewswire)
Feb-12-26 08:00AM	Here Are Thursdays Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More (24/7 Wall St.)
Dec-26-25 05:44PM	Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) (GlobeNewswire) +5.48%
Dec-09-25 07:00AM	Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors (GlobeNewswire)
Dec-02-25 07:01AM	Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK in Japan to Reduce Cisplatin-Induced Hearing Loss (GlobeNewswire)
Nov-26-25 05:59AM	Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-19-25 07:03AM	Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption (GlobeNewswire) -6.51%
Nov-18-25 08:30AM	Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada (GlobeNewswire)
Nov-17-25 04:15PM	Fennec Pharmaceuticals Announces Closing of Offering of Common Shares (GlobeNewswire) +11.32%
Nov-13-25 11:11PM	Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada (GlobeNewswire)
11:07PM	Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares (GlobeNewswire)
05:10PM	Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:08PM	Fennec Pharmaceuticals Announces Proposed Offering of Common Shares (GlobeNewswire)
04:01PM	Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-12-25 05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 06:00PM	Niagen Bioscience (NAGE) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-30-25 10:00AM	Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-22-25 10:19AM	Are Options Traders Betting on a Big Move in Fennec Pharmaceuticals Stock? (Zacks)
Oct-15-25 04:20AM	New Strong Sell Stocks for Oct. 15th (Zacks) +5.86%
Oct-06-25 09:40AM	Day One Biopharmaceuticals (DAWN) Moves 7.0% Higher: Will This Strength Last? (Zacks)
Sep-19-25 09:43AM	Is the Options Market Predicting a Spike in Adherex Technologies Stock? (Zacks)
Aug-14-25 07:20AM	Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -6.37%
06:08AM	Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update (GlobeNewswire)
Aug-13-25 05:15PM	Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +12.00%
Aug-11-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:12AM	Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025 (GlobeNewswire)
Aug-07-25 07:05PM	Concentra Group (CON) Matches Q2 Earnings Estimates (Zacks)
Jul-31-25 09:40AM	Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? (Zacks)
Jul-15-25 08:50AM	Recent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's Why (Zacks)
Jun-03-25 04:31PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
May-14-25 10:51AM	The Joint Misses Q1 Earnings Estimates on Rising Expenses (Zacks)
03:07AM	Fennec Pharmaceuticals Inc (FENC) Q1 2025 Earnings Call Highlights: Strong Sales Growth Amid ... (GuruFocus.com)
May-13-25 11:33PM	Q1 2025 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
11:06AM	Acadia Healthcare Q1 Earnings Top Estimates on Rising Admissions (Zacks)
07:15AM	Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:03AM	Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.38%
May-09-25 06:26PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) (Zacks)
May-08-25 06:05PM	AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:17PM	Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire)
May-07-25 05:35PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Zacks)
Apr-30-25 09:55AM	Wall Street Analysts See an 113.25% Upside in Adherex Technologies (FENC): Can the Stock Really Move This High? (Zacks)
Apr-10-25 09:35AM	Down -22.15% in 4 Weeks, Here's Why Adherex Technologies (FENC) Looks Ripe for a Turnaround (Zacks)
Mar-21-25 10:21AM	Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? (Zacks)
Mar-11-25 03:00AM	Fennec Pharmaceuticals Inc (FENC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:31AM	Q4 2024 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-10-25 06:03AM	Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.19%
Mar-06-25 04:22PM	Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025 (GlobeNewswire)
Feb-07-25 07:00AM	Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI In Germany (GlobeNewswire)
Dec-20-24 06:16AM	Fennec Pharmaceuticals Announces Pedmarqsi Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales (GlobeNewswire)
Dec-19-24 06:13AM	Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management (GlobeNewswire)
Dec-12-24 07:01AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-13-24 06:27AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conference (GlobeNewswire) +5.91%
Nov-09-24 02:00AM	Fennec Pharmaceuticals Inc (FENC) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Nov-07-24 06:13AM	Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.92%
Oct-31-24 06:23AM	Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-28-24 06:23AM	Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth (GlobeNewswire) +11.56%
Sep-05-24 06:56AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 01:57AM	Q2 2024 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -8.89%
Aug-13-24 06:05AM	Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.40%
Aug-06-24 04:31PM	Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 (GlobeNewswire)
Aug-05-24 06:26AM	Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director (GlobeNewswire)
Jul-29-24 06:15AM	3 Dirt-Cheap Stocks Under $10 That Could EXPLODE! (InvestorPlace)
Jul-15-24 08:32AM	Implied Volatility Surging for Fennec (FENC) Stock Options (Zacks)
Jul-01-24 06:00AM	Fennec Pharmaceuticals Announces Management Change (GlobeNewswire)
Jun-25-24 04:35PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
May-15-24 08:44AM	HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating (MT Newswires)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MARCO BRUGHERA	Director	Nov 13 '26	Proposed Sale	12.00	20,000	240,000		Nov 13 04:06 PM
Brughera Marco Maria	Director	Sep 15 '26	Option Exercise	2.11	15,545	32,800	15,545	Sep 16 04:05 PM
Brughera Marco Maria	Director	Sep 15 '26	Sale	10.29	15,545	159,958	0	Sep 16 04:05 PM
MARCO BRUGHERA	Director	Sep 15 '26	Proposed Sale	10.30	15,545	160,070		Sep 15 04:06 PM
ROSTISLAV RAYKOV	Former Director	Sep 01 '26	Proposed Sale	12.12	10,000	121,177		Sep 01 04:13 PM
Raykov Rosty	Former Director	Sep 01 '26	Sale	12.11	10,000	121,100	124,411	Sep 01 04:05 PM
Sayad Pierre Sargis	Chief Medical Officer	Aug 31 '26	Sale	12.18	12,000	146,160	9,519	Aug 31 08:15 PM
PIERRE S SAYAD	Officer	Aug 31 '26	Proposed Sale	12.18	12,000	146,170		Aug 31 04:07 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Aug 28 '26	Option Exercise	5.10	21,928	111,833	239,603	Aug 28 05:42 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Aug 27 '26	Sale	11.78	75,000	883,500	217,675	Aug 28 05:42 PM
ROBERT ANDRADE	Officer	Aug 27 '26	Proposed Sale	11.79	75,000	883,898		Aug 27 04:20 PM
Raykov Rosty	Former Director	Aug 03 '26	Sale	9.58	10,000	95,800	131,633	Aug 04 04:05 PM
ROSTISLAV RAYKOV	Former Director	Aug 03 '26	Proposed Sale	9.58	10,000	95,835		Aug 03 05:05 PM
Raykov Rosty	Former Director	Jul 01 '26	Option Exercise	2.45	15,597	38,213	148,454	Jul 02 04:05 PM
Raykov Rosty	Former Director	Jul 01 '26	Sale	10.41	9,599	99,926	138,855	Jul 02 04:05 PM
ROSTISLAV RAYKOV	Director	Jul 01 '26	Proposed Sale	10.42	9,599	99,987		Jul 01 04:29 PM
Raykov Rosty	Director	Jun 01 '26	Option Exercise	2.45	15,597	38,213	139,826	Jun 02 04:05 PM
Raykov Rosty	Director	Jun 01 '26	Sale	9.62	9,747	93,766	130,079	Jun 02 04:05 PM
ROSTISLAV RAYKOV	Director	Jun 01 '26	Proposed Sale	9.62	9,747	93,814		Jun 01 04:14 PM
RALLIS CHRIS A	Director	May 11 '26	Option Exercise	2.44	14,344	34,999	71,423	May 12 04:05 PM
RALLIS CHRIS A	Director	May 11 '26	Sale	7.04	8,346	58,756	63,077	May 12 04:05 PM
CHRIS A RALLIS	Director	May 11 '26	Proposed Sale	7.05	8,346	58,833		May 11 04:16 PM
Raykov Rosty	Director	May 01 '26	Option Exercise	2.45	15,598	38,215	132,232	May 01 05:00 PM
Raykov Rosty	Director	Apr 30 '26	Option Exercise	0.00	2,778	0	116,634	May 01 05:00 PM
Raykov Rosty	Director	May 01 '26	Sale	6.47	10,781	69,753	121,451	May 01 05:00 PM
ROSTISLAV RAYKOV	Director	May 01 '26	Proposed Sale	6.47	10,781	69,762		May 01 04:15 PM
Evans Terry L	Chief Commercial Officer	Apr 30 '26	Option Exercise	0.00	168	0	20,847	May 01 04:05 PM
Cioffi Christiana Marie	Chief Strategy Officer	Apr 30 '26	Option Exercise	0.00	155	0	24,020	May 01 04:05 PM
Hackman Jeffrey S.	Chief Executive Officer	Apr 30 '26	Option Exercise	0.00	1,159	0	61,666	May 01 04:05 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Apr 30 '26	Option Exercise	0.00	1,703	0	287,566	May 01 04:05 PM
Sayad Pierre Sargis	Chief Medical Officer	Apr 30 '26	Option Exercise	0.00	168	0	20,847	May 01 04:05 PM
Cioffi Christiana Marie	Chief Strategy Officer	Mar 31 '26	Option Exercise	0.00	17,264	0	21,964	Apr 02 04:05 PM
Cioffi Christiana Marie	Chief Strategy Officer	Mar 28 '26	Option Exercise	0.00	1,901	0	23,865	Apr 02 04:05 PM
Hackman Jeffrey S.	Chief Executive Officer	Mar 31 '26	Option Exercise	0.00	17,854	0	46,564	Apr 02 04:05 PM
Hackman Jeffrey S.	Chief Executive Officer	Mar 28 '26	Option Exercise	0.00	13,943	0	60,507	Apr 02 04:05 PM
Raykov Rosty	Director	Apr 01 '26	Option Exercise	2.45	15,598	38,215	124,802	Apr 02 04:05 PM
Raykov Rosty	Director	Apr 01 '26	Sale	6.31	10,946	69,069	113,856	Apr 02 04:05 PM
Sayad Pierre Sargis	Chief Medical Officer	Mar 31 '26	Option Exercise	0.00	18,627	0	18,627	Apr 02 04:05 PM
Sayad Pierre Sargis	Chief Medical Officer	Mar 28 '26	Option Exercise	0.00	2,052	0	20,679	Apr 02 04:05 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Mar 31 '26	Option Exercise	0.00	16,937	0	273,593	Apr 02 04:05 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Mar 28 '26	Option Exercise	0.00	12,270	0	285,863	Apr 02 04:05 PM
Evans Terry L	Chief Commercial Officer	Mar 31 '26	Option Exercise	0.00	18,627	0	18,627	Apr 02 04:05 PM
Evans Terry L	Chief Commercial Officer	Mar 28 '26	Option Exercise	0.00	2,052	0	20,679	Apr 02 04:05 PM
ROSTISLAV RAYKOV	Director	Apr 01 '26	Proposed Sale	6.31	10,946	69,073		Apr 01 04:38 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Mar 26 '26	Option Exercise	5.10	13,072	66,667	256,656	Mar 26 04:30 PM
Cioffi Christiana Marie	Chief Strategy Officer	Mar 26 '26	Option Exercise	4.23	4,700	19,881	4,700	Mar 26 04:29 PM
Raykov Rosty	Director	Mar 02 '26	Option Exercise	2.45	15,598	38,215	114,075	Mar 03 04:05 PM
Raykov Rosty	Director	Mar 02 '26	Sale	8.36	10,079	84,260	103,996	Mar 03 04:05 PM
ROSTISLAV RAYKOV	Director	Mar 02 '26	Proposed Sale	8.37	10,079	84,354		Mar 02 05:07 PM
Hackman Jeffrey S.	Chief Executive Officer	Feb 18 '26	Option Exercise	0.00	13,710	0	28,710	Feb 19 06:44 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Feb 18 '26	Option Exercise	0.34	29,735	9,996	242,393	Feb 19 06:43 PM
Raykov Rosty	Director	Feb 02 '26	Option Exercise	2.45	15,598	38,215	108,826	Feb 02 04:54 PM
Raykov Rosty	Director	Feb 02 '26	Sale	7.76	10,349	80,308	98,477	Feb 02 04:54 PM
ROSTISLAV RAYKOV	Director	Feb 02 '26	Proposed Sale	7.76	10,349	80,339		Feb 02 04:32 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Jan 23 '26	Option Exercise	2.45	10,000	24,500	211,100	Jan 23 04:56 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Jan 15 '26	Option Exercise	2.45	10,000	24,500	201,100	Jan 15 04:05 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Jan 07 '26	Option Exercise	2.45	14,184	34,751	191,100	Jan 07 04:28 PM
Raykov Rosty	Director	Jan 02 '26	Option Exercise	2.45	15,598	38,215	98,332	Jan 05 04:05 PM
Raykov Rosty	Director	Jan 02 '26	Sale	7.60	10,312	78,371	88,020	Jan 05 04:05 PM
ROSTISLAV RAYKOV	Director	Jan 02 '26	Proposed Sale	7.61	10,312	78,471		Jan 02 04:19 PM
Southpoint Capital Advisors LP	10% Owner	Dec 24 '25	Sale	7.50	1,000,000	7,500,000	2,744,741	Dec 29 04:34 PM
Raykov Rosty	Director	Dec 05 '25	Sale	7.54	10,000	75,400	77,526	Dec 05 06:41 PM
ROSTISLAV RAYKOV	Director	Dec 05 '25	Proposed Sale	7.54	10,000	75,444		Dec 05 05:13 PM
Southpoint Capital Advisors LP	10% Owner	Nov 18 '25	Sale	8.79	19,341	170,048	3,744,741	Nov 20 04:07 PM
Southpoint Capital Advisors LP	10% Owner	Nov 17 '25	Sale	8.79	85,918	755,193	3,764,082	Nov 17 08:42 PM

Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

CEO & DirectorMr. Jeffrey S. Hackman

Chief Financial OfficerMr. Robert C. Andrade

Ph.D.Dr. Pierre S. Sayad M.S.

Chief Commercial OfficerMr. Terry Evans

Chief Strategy OfficerMs. Christiana Cioffi M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

FENC

Fennec Pharmaceuticals Inc

Upgrade your Finviz experience

All the Features.
Half the Price.